Power3 Medical's Goldknopf Elected to the Hunter College Hall of Fame

Market Wire, April, 2009

Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in the research of neurodegenerative disease and cancer biomarkers, announced today that the Company's president and chief scientific officer, Dr. Ira L. Goldknopf, will be inducted into the Hunter College Hall of Fame on May 1, 2009. The Hall of Fame has been recognizing Hunter College's most accomplished alumni since 1972. Dr. Goldknopf graduated from Hunter College of the City University of New York in 1967 with a bachelor of arts degree. He received his Ph.D. from Kansas State University in 1971.

"This honor is being bestowed upon you for the exemplary work that you have done in the field of biochemistry," wrote James W. Davis, chair, 2009 Hall of Fame committee. The award citation from Hunter College reads: "A pioneer in the scientific field of Proteomics... at Baylor College of Medicine, Ira Goldknopf and Harris Busch made the earliest proteomic discovery. Through this work, and that of many others over the years, this system called the Ubiquitin Conjugation System is now known to play a major role in the management of the inventories of proteins in the cell, cell proliferation, programmed cell death and most regulatory functions of health and disease at the cellular level."

Founder and Chief Scientific Officer of Power3 Medical Products, Inc., Dr. Goldknopf and his team discovered the serum proteomic tests for early detection of breast cancer, for early diagnosis of Alzheimer's, Parkinson's, ALS and other tests and drug targets. He has been awarded the NASA Space Act Award for the invention of commercial applications for NASA technology and, while he was not named a laureate, he has been cited for his contributions to the 2004 Nobel Prize in Chemistry. He is the author of more than 70 publications, book chapters and patents.

Helen R. Park, Power3's interim CEO, stated that: "Power3 is excited that Hunter College recognizes the importance of Dr. Goldknopf's contributions to proteomics discovery and the development of diagnostic tests that will benefit the medical community and all of health care."

About Power3 Medical Products, Inc.

Power3 Medical Products ( www.power3medical.com ) is a leading bio-medical company engaged in the commercialization of diagnostic tests and drug targets for neurodegenerative disease and cancer, employing proteomic biomarkers, pathways, and mechanisms of diseases. Power3's patent-pending technologies are being used to develop diagnostic tests for the early detection, prognosis, response to therapy, as well as targeted therapy and personalized medicine. Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer's disease and Parkinson's disease (NuroPro®) in 2009, which will be followed by a filing with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers that it has discovered in a broad range of diseases. Power3 utilizes these biomarkers as the basis of highly selective blood-based tests for Alzheimer's and Parkinson's diseases, ALS, as well as breast cancer.

Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement contained herein. Specific forward looking statements made in this news release include, but are not limited to, the statement that Power3 is ready to begin marketing, and the launch of its NuroPro and BC-SeraPro blood test kits to the health care industry.

Contact: Power3 Medical Products, Inc. Helen Park CEO 281-466-1600 Email Contact or Investor Relations: Equiti-trend Advisors LLC (800) 953-3350 toll-free (858) 436-3350 local or international